Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer—Just About Ready for Prime-Time?

As targeted molecular therapies and immuno-oncology have become pivotal in the management of patients with lung cancer, the essential requirement for high throughput analyses and clinical validation of biomarkers has become even more intense, with response rates maintained in the 20%–30% range. More...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Hofman, Paul, Badoual, Cécile, Henderson, Fiona, Berland, Léa, Hamila, Marame, Long-Mira, Elodie, Lassalle, Sandra, Roussel, Hélène, Hofman, Véronique, Tartour, Eric, Ilié, Marius
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6468415/
https://ncbi.nlm.nih.gov/pubmed/30818873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11030283
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados